Serious complications of chimeric antigen receptor T cell therapy
10.3760/cma.j.issn.1673-4912.2022.08.004
- VernacularTitle:嵌合抗原受体T细胞治疗的常见严重并发症
- Author:
Kang AN
1
;
Yanjing TANG
Author Information
1. 上海交通大学医学院附属上海儿童医学中心血液肿瘤科 200127
- Keywords:
Chimeric antigen receptor T cell therapy;
Toxicity;
Malignant tumor
- From:
Chinese Pediatric Emergency Medicine
2022;29(8):589-594
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T cell (CAR-T) therapy is becoming the most promising treatment method in children and adolescent with refractory and relapse malignancies.While CAR-T cells exhibit powerful antitumour activity, this therapy has been associated with unique and significant toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) by triggering immune effector cells, even develop rapid and life-threatening cardiovascular, respiratory and/or neurological dysfunction.The assessment and grading of these adverse events vary widely in different clinical trials and institutions.For integrating the definitions and grading systems for toxicities from immune effector responses, in 2018, the American Bone Marrow Transplantation Society proposed consensus definitions and grading which is objective and easy to apply for CRS and ICANS.It helps clinicians and nurses make early critical care assessment and guide critical care interventions, thereby improving the efficacy and safety of CAR-T therapy.
